Clinical trials: Cervical Cancer Squamous Cell
Metastatic Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma
Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer
Gemcitabine is a novel analog of the nucleoside deoxycytidine that acts via inhibition of DNA synthesis.Docetaxel is a semisynthetic taxane and promotes microtubule assembly and inhibits microtubule depolymerization.
- Trial name
- NCT01469598
- Testing
- Gemcitabine/Docetaxel
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Samsung Medical Center
Esophageal Squamous Cell Carcinoma
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
This study will explore the efficacy and safety of benmelstobart combined with radiochemotherapy compared to radiochemotherapy alone as neoadjuvant treatment for esophageal squamous cell carcinoma.
- Trial name
- NCT06637163
- Testing
- Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy, Paclitaxel + Carboplatin + Radiotherapy
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
Oral Cavity Squamous Cell Carcinoma
Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience
Sentinel node biopsy is a suitable alternative to END and is recommended in standard guidelines. Investigators have been doing SNB in their department to standardize the process for the last two years.
- Trial name
- NCT05950737
- Testing
- Sentinel node biopsy
- Where
- India
- Volunteers
- 115 people
- Sponsor
- Tata Memorial Hospital
Squamous Cell Carcinoma of the Oral Cavity
CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
This trial is to investigate the use of nivolumab in sequence with standard of care surgery and radiation/chemoradiation in locally advanced oral cavity Squamous cell carcinoma of the oral cavity.
- Trial name
- NICO (NCT03721757)
- Testing
- Nivolumab, Surgery, Radiotherapy, Nivolumab, Surgery, Chemoradiotherapy
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
This phase III trial compares cetuximab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer that may have spread from where it first…
- Conditions
- Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT07441681
- Testing
- Biospecimen Collection, Carboplatin, Cetuximab
- Where
- 150 sites in United States
- Volunteers
- 454 people
- Sponsor
- NRG Oncology
Esophageal Cancer
PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PNU-93914 in treating patients who have locally…
- Trial name
- NCT00016900
- Testing
- liposomal paclitaxel
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma
Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer
Multi-centric, one arm phase II study. The first phase of the study will consist of an evaluation of the initial dental state of each subject based on a stomatological examination, an orthopantomogram, two bitewing radiographs…
- Trial name
- StomRay (NCT04452032)
- Testing
- Dental avulsion, Radiotherapy
- Where
- 3 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- Jules Bordet Institute
Squamous Cell Cancer of Head and Neck (SCCHN)
Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer
This is a randomized, single centre, single blinded prospective study comparing the standard of care imaging guided radiation therapy and daily adaptive radiotherapy (ART) for submandibular gland-sparing in head and neck cancer
- Trial name
- RTL-DART (NCT07348887)
- Testing
- Daily adaptive radiation therapy, Image guided radiation therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Head and Neck Squamous Cell Carcinoma
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
This trial is main evaluate the efficacy and safety of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma
- Trial name
- NCT04857164
- Testing
- Pembrolizumab combined with Chemotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Yuankai Shi
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity
The objective of the UPGRADE-RT trial is to investigate whether de-escalation of elective radiation dose and introduction of an intermediate dose-level in the treatment of head and neck cancer will results in less radiation…
- Trial name
- UPGRADE-RT (NCT02442375)
- Testing
- standard dose prescription, FDG-PET guided gradient dose prescription
- Where
- 5 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- Radboud University Medical Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
The rationale for the new sequence of pulsed dose chemotherapy proposed in this trial is based on the hypotheses that current standard dosing of chemotherapy plus pembrolizumab ultimately suppresses the immune system and has a…
- Trial name
- NCT06052839
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dan Zandberg
Cervical Cancer
Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00039338
- Testing
- conventional surgery, neoadjuvant chemotherapy, brachytherapy
- Where
- 24 sites in Austria, Belgium and 6 more
- Volunteers
- 686 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flaps
Patients undergoing free flap reconstructive surgery at University of California, Davis Medical Center (UCDMC) will be assigned randomly into no intervention group (immediate post operative care in an ICU) or intervention group…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Trauma
- Trial name
- ICU (NCT03340038)
- Testing
- Non-ICU Specialty ward
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- University of California, Davis
Oesophageal Squamous Cell Carcinoma, Oesophageal Cancer
Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms
Oesophageal Squamous Cell Carcinoma (OSCC) is a cancer of the food pipe that affects around 2000 patients in the UK every year. It is often detected at an advanced stage, resulting in poor survival (5-year survival less than…
- Trial name
- ViSON (NCT06169163)
- Testing
- Exhaled breath sampling
- Where
- 13 sites in United Kingdom
- Volunteers
- 518 people
- Sponsor
- Imperial College London
Head and Neck Cancer, Lip Cancer
Microbiome in Head and Neck Squamous Cell Carcinoma
This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.
- Conditions
- Head and Neck Cancer, Lip Cancer, Oral Cancer, Pharynx Cancer
- Trial name
- NCT05837221
- Testing
- Metagenomic sequencing, Metabolic analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Colorado, Denver
HPV-Related Oropharynx Squamous Cell Carcinoma
The Minimalist Trial-2
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA.
- Trial name
- MINT-2 (NCT06702033)
- Testing
- Radiation therapy, Cisplatin, Surgery
- Where
- 3 sites in United States
- Volunteers
- 142 people
- Sponsor
- Washington University School of Medicine
Oral Cancer, Oropharynx Cancer
Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC
This is a multicentric randomized phase III trial comparing conventional radiotherapy with concomitant chemotherapy versus accelerated radiotherapy with concomitant chemotherapy versus very accelerated radiotherapy in patients…
- Conditions
- Oral Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer
- Trial name
- NCT00158652
- Testing
- Conventional radiotherapy 70 Gy in 7 weeks, middle accelerated radiotherapy 70 Gy in 6 weeks, very accelerated radiotherapy 64.8 Gy in 3.5 weeks
- Where
- 2 sites in France
- Volunteers
- 840 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Esophageal Neoplasms
The Predictive Value of CT-PET in Esophageal Cancer
A major focus of research in oncology is to identify patients who, following induction therapy, have a complete pathologic response, presenting opportunities for novel trials, including extended therapy or non-operative…
- Trial name
- NCT02385604
- Where
- Ireland
- Volunteers
- 250 people
- Sponsor
- St. James's Hospital, Ireland
Locally Advanced Head and Neck Squamous Cell Carcinoma
CLEAR (Cervical Lymphatic Exclusion in Adjuvant Radiation)
The goal of this clinical trial is to learn if selectively omitting postoperative cervical irradiation is a safe and feasible treatment strategy for patients with resected, locally advanced squamous cell carcinoma of the head and…
- Trial name
- CLEAR (NCT07755449)
- Testing
- IMRT OR VMAT Radiotherapy excluding cervical radiation
- Where
- Spain
- Volunteers
- 101 people
- Sponsor
- Institut Català d'Oncologia